Search

Effect of Virtual Reality on Freezing Phenomenon, Balance, Functional Mobility, Participation in Parkinson's Patients

Trial N/A Unknown April 29, 2024

Subthalamic Nucleus Stimulation Electrode and Psychiatric Lesion Effects in Parkinson's Disease

Trial N/A Completed April 28, 2024

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Trial Phase 1 Completed April 28, 2024

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Trial Phase 1 Unknown April 28, 2024

Diaphragmatic Thickness and Pulmonary Function in Parkinson's Disease

Trial N/A Completed April 25, 2024

Virtual Reality and Fear of Falling in Parkinson's Disease

Trial N/A Unknown April 25, 2024

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Trial Phase 1 Completed April 24, 2024

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Trial Phase 3 Completed April 24, 2024

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Trial Phase 2 Completed April 24, 2024

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Trial Phase 3 Completed April 24, 2024

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Trial Phase 4 Completed April 24, 2024

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Trial Phase 3 Completed April 24, 2024

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Trial Phase 3 Completed April 24, 2024

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

Trial Phase 2 Unknown April 24, 2024

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Trial Phase 2 Completed April 24, 2024

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Trial Phase 2 Completed April 24, 2024

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Trial Phase 3 Completed April 24, 2024

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Trial Phase 3 Completed April 24, 2024

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Trial Phase 2 Completed April 24, 2024

Keep On Keep Up for Parkinson's

Trial N/A Unknown April 23, 2024